Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06004986 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema

Study acronym: DUPI REDUCE
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Oct 15, 2024 to Oct 1, 2025 Completion date: Dec 31, 2024 to Dec 31, 2025v4 Show 1 more changeShow less
    • Completion date: Dec 31, 2024 to Dec 31, 2025
  2. Trial status: Not Yet Recruiting to Recruiting Study sites: 1 to 2 · Start date changed from estimate of Aug 15, 2023 to Aug 14, 2023v3 Show 2 more changesShow less
    • Study sites: 1 to 2
    • Start date changed from estimate of Aug 15, 2023 to Aug 14, 2023
  3. Secondary endpoints: details revised at 8 of 13 entriesv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this randomized controlled trial is to study the (cost)effectiveness of extending the intervals between dupilumab doses in patients with well-controlled atopic eczema, while considering physician- and patient-reported disease severity, quality of life, and dupilumab serum trough levels. Patients will be divided randomly into three groups, receiving dupilumab 300 mg every 2 weeks, every 3 weeks, or every 4 weeks. Researchers will then compare the outcomes among these three groups.
Trial Details
NCT Number NCT06004986
Lead Sponsor Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Collaborators: Erasmus Medical Center, Prothya Biosolutions
Conditions Atopic Dermatitis, Atopic Dermatitis Eczema
Enrollment 216 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov